MedPageToday The modified vaccinia Ankara-Bavarian Nordic mpox vaccine (MVA-BN; Jynneos) generated robust immune responses in adolescents against mpox and was safe, according to an interim analysis of a phase II clinical trial.
Two doses of the vaccine generated geometric mean titers (GMT) in adolescents (470.3, 95% CI 422.3-523.8) that were higher than titers in adults (293.2, 95% CI 249.8-344.2), with a geometric mean titer ratio (GMTR) of 1.60 (95% CI 1.32-1.95), reported C. Mary Healy, MD of Baylor College of Medicine in Houston, during the IDWeek annual meeting in Los Angeles.
Fair Use Notice
UNMC Global Center for Health Security staff curate publicly available news and information for educational and informational purposes. Brief excerpts of published articles may be displayed under principles of Fair Use, with credit and links provided to the source publications. All copyrights remain the property of their respective owners.